- Medication and Pregnancy KB

Study	Type of data	Exposure measurement	Outcome assessment	Adjustment
Gold, 2016	retrospective cohort	Clinics visits occurred every 4 weeks for daclizumab administration and safety and tolerability assessments; during the extension studies, visits were every 4–12 weeks.	Investigators were required to report pregnancies and the subsequent outcome.	None